EMA Authorised: Epclusa (sofosbuvir;velpatasvir) — Gilead Sciences Ireland UC

View source ↗

Summary

EPAR entry indicating EMA authorised Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C, with Gilead as MAH and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Epclusa (sofosbuvir/velpatasvir)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: Gilead Sciences Ireland UC. Decision date: 07/08/2023. Accelerated assessment